Hypoglycemia: symptom or diagnosis?

J Pediatr Nurs

Formerly of Hyperinsulinism Center, Division of Endocrinology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Published: February 2012

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pedn.2011.10.005DOI Listing

Publication Analysis

Top Keywords

hypoglycemia symptom
4
symptom diagnosis?
4
hypoglycemia
1
diagnosis?
1

Similar Publications

Mitochondrial HMG-CoA synthase deficiency.

Mol Genet Metab

January 2025

Clinical Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium; Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium. Electronic address:

Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2) deficiency is a rare, potentially life-threatening autosomal recessive disorder resulting from mutations in the HMGCS2 gene, leading to impaired ketogenesis. We systematically reviewed the clinical presentations, biochemical and genetic abnormalities in 93 reported cases and 2 new patients diagnosed based on biochemical findings. Reported onset ages ranged from 3 months to 6 years, mostly before the age of 3.

View Article and Find Full Text PDF

Introduction: This analysis aimed to investigate diabetes-specific psychological outcomes among adults with type 1 diabetes (T1D) using hybrid closed-loop (HCL) versus standard therapy.

Research Design And Methods: In this multicenter, open-label, randomized, controlled, parallel-group clinical trial, adults with T1D were allocated to 26 weeks of HCL (MiniMed™ 670G) or standard therapy (insulin pump or multiple daily injections without real-time continuous glucose monitoring). Psychological outcomes (awareness and fear of hypoglycemia; and diabetes-specific positive well-being, diabetes distress, diabetes treatment satisfaction, and diabetes-specific quality of life (QoL)) were measured at enrollment, mid-trial and end-trial.

View Article and Find Full Text PDF

Background: This study evaluates the efficacy and safety of sitagliptin versus gliclazide, combined with metformin, in treatment-naive patients with type 2 diabetes mellitus (T2DM) and glucotoxicity.

Methods: In this single-center, randomized, controlled noninferiority trial, 129 treatment-naive patients with T2DM with glucotoxicity (fasting plasma glucose [FPG] ≥ 200 mg/dL and glycated hemoglobin ≥ 9.0%) were randomized to receive sitagliptin plus metformin (n = 66) or gliclazide plus metformin (n = 63) for 12 weeks.

View Article and Find Full Text PDF

Background: There is a lack of data on the validation and diagnostic performance of the Freestyle Optium Neo-H (Freestyle) and Centrivet GK (Centrivet) devices for the diagnosis of hypoglycaemia, hyperglycaemia and hyperketonaemia in goats.

Objectives: The aim of the present study was to validate the Freestyle and Centrivet for the analysis of whole blood beta-hydroxybutyric acid (BHBA) and to validate the Freestyle for the analysis of whole blood glucose concentrations using the reference method (RM) in goat blood collected from the jugular and ear veins.

Methods: Venous blood samples were utilised to assess glucose and BHBA concentrations using the Freestyle, Centrivet and RM.

View Article and Find Full Text PDF

A 37-year-old man presented with symptoms of polyuria and weight loss over the past year. Initial laboratory examination showed elevated blood glucose level (468 mg/dL [25.9 mmol/L]; normal reference range [RR], 75-109 mg/dL [4.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!